Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02574962

Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy

Chronic Inflammatory Demyelinating Polyneuropathy Clinical Trial

Official title:
Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy

Clinical Trial Summary

The purpose of this pilot study is to assess the safety and efficacy of Acthar® Gel in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) patients.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

  • Chronic Inflammatory Demyelinating Polyneuropathy
  • Polyneuropathies
  • Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Clinical Trial Details
NCT number NCT02574962
Study type Interventional
Source University of Kansas Medical Center
Contact
Status Withdrawn
Phase Phase 2
Start date August 2015
Completion date July 2018
View Details
See also
  Status Clinical Trial Phase
Completed NCT02465359 - Subcutaneous Immunoglobulin for CIDP N/A
Recruiting NCT05584631 - IVIG vs SCIG in CIDP Phase 1
Withdrawn NCT01236456 - High-dose Cyclophosphamide for Moderate to Severe Refractory Chronic Inflammatory Demyelinating Polyneuropathy Phase 2
Terminated NCT03779828 - Evaluating the Effectiveness of Telemonitoring System in the Management of Patients With CIDP
Completed NCT01184846 - Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy Phase 3
Recruiting NCT05011006 - NT-3 Levels and Function in Individuals With CMT
Recruiting NCT06290141 - A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Phase 3
Completed NCT01379833 - Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy
Completed NCT02414490 - IVIg Treatment-Related Fluctuations in CIDP Patients Using Daily Grip Strength Measurements
Completed NCT01545076 - Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20) Phase 3
Active, not recruiting NCT00716066 - Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases Phase 2
Recruiting NCT04672733 - Hizentra® in Inflammatory Neuropathies - pHeNIx Study
Not yet recruiting NCT04480450 - Rituximab in Chronic Inflammatory Demyelinating Polyneuropathy Phase 2
Completed NCT01931644 - At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
Not yet recruiting NCT05219383 - Clinical and Electrophysiological Patterns of Chronic Dysimmune Polyneuropathy
Completed NCT02111590 - Immunoglobulin Dosage and Administration Form in CIDP and MMN N/A
Recruiting NCT04292834 - A Registered Cohort Study of Immune-Mediated Neuropathies
Terminated NCT03772717 - Non-invasive Vagus Nerve Stimulation (nVNS) in Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) N/A
Completed NCT00278629 - Hematopoietic Stem Cell Transplantation in Chronic Inflammatory Demyelinating Polyneuropathy Phase 2
Recruiting NCT02372149 - IVIg for Demyelination in Diabetes Mellitus Phase 4